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Importance—Most primary care clinicians lack the skills and resources to offer effective 
lifestyle and medication counseling to reduce coronary heart disease (CHD) risk. Thus, effective 
and feasible CHD prevention programs are needed for typical practice settings.
Objective—To assess the effectiveness, acceptability, and cost-effectiveness of a combined 
lifestyle and medication intervention to reduce CHD risk offered in counselor-delivered and web-
based formats.
Design—Comparative effectiveness trial.
Setting—Five diverse family medicine practices in North Carolina.
Participants—Established patients, age 35–79, with no known cardiovascular disease, and at 
moderate to high risk for CHD -- 10 year Framingham Risk Score (FRS) ≥ 10%.
Intervention—Participants were randomized to counselor-delivered or web-based format, each 
including 4 intensive and 3 maintenance sessions. After randomization, both formats utilized a 
web-based decision aid showing potential CHD risk reduction associated with lifestyle and 
medication risk reducing strategies. Participants chose the risk reducing strategies they wished to 
follow.
Main Outcome and Measures—Outcomes were assessed at 4 and 12 months; the primary 
outcome was within group change in FRS at 4 month follow-up. Other measures included 
standardized assessments of blood pressure, blood lipids, lifestyle behaviors, and medication 
adherence. Acceptability and cost-effectiveness were also assessed.
Results—Of 2,274 screened patients, 385 were randomized (192 counselor; 193 web): mean age 
62 years, 24% African American, and mean FRS 16.9%. Follow-up at 4 and 12 months was 91% 
and 87%, respectively. There was a sustained reduction in FRS at both 4 (primary outcome) and 
12 month follow-up: for counselor, −2.3% (95% CI: −3.0% to −1.6%) and −1.9% (−2.8% to 
−1.1%) and for web, −1.5% (−2.2% to −0.9%) and −1.7%, (−2.6% to −0.8%) respectively. At 4 
month follow-up, the adjusted difference in FRS between groups was −1.0% (95% CI −1.8% to 
−0.1%, p = 0.03) at 12 month follow-up, it was −0.6% (95% CI, −1.7% to 0.5%, p = 0.30). The 12 
month costs from the payer perspective were $207 and $110 per person for the counselor and web 
interventions respectively.
Conclusions and Relevance—Both intervention formats reduced CHD risk through 12 month 
follow-up. The web format was less expensive.
Introduction
A healthy lifestyle1,2 and appropriate medications3–5 can substantially reduce the risk for 
coronary heart disease (CHD), yet getting patients to change their lifestyle and initiate and 
adhere to risk reducing medication can be difficult to achieve in clinical practice. In 
particular, most primary care clinicians lack the skills6,7 and resources8 to offer effective 
lifestyle and medication counseling to reduce CHD risk. Thus, to improve CHD prevention 
in primary care practices, where half of Americans are seen annually,9 clinicians need access 
to effective and feasible CHD prevention programs that could be implemented in their 
practice settings.
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While many primary-care based programs to reduce CHD risk have been previously tested, 
these programs have limitations.10,11 Most have not jointly addressed lifestyle change and 
medication optimization and few have taken a patient-centered approach that informs 
patients about the relative merits of strategies to reduce CHD risk and encourages them to 
select their preferred risk reducing strategies. Further, few have been evaluated in 
comparative effectiveness studies12,13 that: 1) compare clinically relevant implementation 
strategies, 2) include a diverse population of participants, 3) include a heterogeneous 
selection of practices, and 4) collect data on a broad range of outcomes.
Given increasing evidence that supports the effectiveness of web-based interventions,14,15 
we developed a combined lifestyle and medication intervention to reduce CHD risk and 
tested it in two formats: counselor-delivered and web-based. While the counselor 
intervention provides human interaction and the potential for a higher degree of tailoring, 
the web intervention offers greater reach, flexibility to patients in the timing and delivery of 
the intervention, and minimizes clinic staff demands and costs.16 In this paper, we report the 
results of a comparative effectiveness trial conducted to assess the effectiveness, 
acceptability, and cost-effectiveness of the intervention when offered in alternative formats.
METHODS
Study Overview
We conducted this study at 5 diverse family medicine practices located in central North 
Carolina. Our primary intent was to determine the comparative effectiveness of the two 
intervention formats on reducing CHD risk as assessed by the Framingham Risk Score 
(FRS).17 Participants were randomized to receive interventions similar in contact time, 
educational content, and individually tailored counseling, but different in format (Figure 1). 
Study outcomes were assessed at 4 and 12 months. Details of the study design, study 
practices, participant enrollment, and intervention components are described elsewhere.17 
The University of North Carolina at Chapel Hill’s Institutional Review Board (IRB) 
approved and monitored this study, with data collected between January 31, 2011 and 
November 26, 2012.
Participants, Enrollment, and Randomization
Participants were established patients (i.e., had at least one office visit in the last 2 years), 
age 35–79, with no known cardiovascular disease (CVD), who were at moderate to high risk 
for CHD (≥ 10% 10-year risk of angina, myocardial infarction, or CHD death) based on 
their FRS. Participants were identified by chart reviews of patients scheduled for routine 
office visits, supplemented by referrals from clinicians and self-referrals based on word-of-
mouth or in response to waiting room flyers. As an initial eligibility screen, the FRS was 
calculated using risk factors assessed by chart review (age, blood pressure, total cholesterol, 
high density lipoprotein cholesterol (HDL-C), diabetes, smoking, aspirin use, and left 
ventricular hypertrophy).17 Diabetes was included in the FRS and was not considered a 
CVD equivalent. Because aspirin was not accounted for by the Framingham risk equation, 
we modelled its effect on CHD risk using a 23% risk reduction for men and 0% reduction 
for women.3 Those with a FRS ≥ 10% were further evaluated by their primary care 
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clinicians who 1) determined if the patient should be excluded for a variety of previously 
described17 medical conditions and 2) approved participation in the overall and physical 
activity component of the study.
Patients screened as eligible attended an enrollment visit, during which study staff obtained 
written informed consent, confirmed inclusion criteria, screened participants for potential 
bleeding risk associated with aspirin, re-assessed smoking status, assessed blood pressure 
using a standard protocol, and obtained a blood sample for study lab assessments. 
Participants’ FRS were re-calculated based on this standardized assessment and, if ≥ 10%, 
they were contacted for the baseline telephone survey. Those completing this survey were 
invited to the first intervention visit, where they were randomized, as previously 
described.17
Intervention
Both intervention formats began with a web-based decision aid, followed by the counseling 
program. As described elsewhere,17 the intervention was based on previously developed and 
tested lifestyle and medication interventions revised to be consistent with the latest evidence 
on CHD risk reduction.
Decision Aid—The decision aid 1) calculated participants’ 10-year FRS, 2) educated 
participants about their CHD risk factors and the pros and cons of risk-reducing strategies, 
and 3) showed participants how much their CHD risk might be reduced by one or more of 
the following: changes in diet, increased physical activity, smoking cessation, initiation of 
aspirin (for men only), or initiation or intensification of statins or hypertension medication. 
The following risk reduction estimates were used: 20–40% for diet,1,17–21 10–20% for 
physical activity,22,23 50% for smoking cessation, and 20–30% depending on type of 
medication (statins, blood pressure medication, and aspirin for men).24 For women who 
indicated an interest in aspirin, the decision aid provided information on stroke risk and the 
potential reduction in stroke with aspirin of 23%. Participants navigated the decision aid 
with the assistance of the health counselor and were encouraged to choose the risk reducing 
strategies they wished to focus on as part of this program.
Counseling—Both formats included 7 counseling sessions: 4 during a 4 month intensive 
phase (each about 45–60 minutes at monthly intervals) followed by 3 during an 8 month 
maintenance phase (each about 15–30 minutes at 2 month intervals). Counseling was 
tailored to choice of risk reducing strategy; diet, physical activity, medications, or any 
combination. To standardize counseling, the sequence, educational content, and tailoring of 
the counselor and web formats was the same. Specifically, both formats used the same set of 
questions to assess baseline habits and barriers. Additionally, counseling sessions included 
identical educational content (including graphics) that were presented in a 3 ring binder for 
counselor format and on a sequence of web pages for web format. Finally, the counselor and 
interactive web progam used the same process to select tailored goals and list first steps. For 
the counselor format, these goals were checked on a sheet; for the web format, they were 
printed.
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Dietary counseling focused on improving carbohydrate and fat quality; physical activity 
counseling focused on walking 7,500 steps or 30 minutes on 5 days each week; and 
medication counseling focused on understanding medication instructions, planning ahead for 
refills, and encouragement to partner with clinician to make good decisions about 
medications to reduce CHD risk. All participants received a cook book, a pedometer for 
self-monitoring, and a guide with information on local resources promoting healthy eating 
and physical activity.. The initial visit was conducted at the clinic, where the counselor 
could assist participants with the web program, if needed. Subsequent visits were conducted 
at the clinic or remotely (by phone for counseling arm or computer for web arm). 
Counseling was conducted by trained health counselors, as previously described.17 Requests 
for medication initiation or intensification were routed to participants’ providers for 
approval.
Outcomes and Measures
Study measures addressed effectiveness, acceptability, and cost-effectiveness and were 
assessed by trained research staff at participating practices and by phone. The primary 
effectiveness measure was within group change in FRS at 4 month follow-up. The FRS was 
calculated using a well-validated Framingham risk equation25 with input of relevant risk 
factor data measured in a standardized fashion and baseline age used for follow-up 
assessments. Pre-specified secondary effectiveness outcomes included between group 
changes in FRS and change in dietary intake, physical activity, smoking, medication 
adherence, blood pressure, blood lipids, and health related quality of life. In addition, an 
analysis of moderators of outcomes was also planned.
Weight, blood pressure, total cholesterol, HDL-C, directly measured low density lipoprotein 
cholesterol (LDL-C), hemoglobin A1c (A1c), high sensitivity C reactive protein (hsCRP), 
alanine aminotransferase (ALT), creatinine, and plasma carotenoids26 were assessed at 
baseline, 4 and 12 months as previously described.17 At the first counseling visit, 
numeracy,27 literacy,28 and medication adherence29 were assessed using validated 
instruments. At follow-up visits, aspirin use was assessed by serum thromboxane level and 
smoking by NicAlert urine test, as previously described.17
The following measures were assessed by telephone at baseline and in-person at 4 and 12 
month follow-up: medication use, fruit and vegetable intake,30 dietary fat quality,31 physical 
activity,32,33 and quality of life (SF-12, Quality Metric, Inc., Lincoln, RI). Medication 
adherence29 and acceptability of the interventions were assessed in-person at 4 and 12-
month follow-up.
Process measures were collected at intervention sessions, by counselor or the web-program. 
Participants were advised to wear an Omron HJ-720ITC pedometer (Omron Healthcare, 
Bannockburn, IL) during the week before study measurement visits. Steps were assessed by 
averaging at least 3 days of 500 or more steps/day during the week prior to the visit. 
Assessment of costs for the cost-effective analysis are described in the Appendix.
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Sample size was based on the hypothesis that both interventions would reduce the FRS by at 
least 1.5 percentage points (absolute risk reduction of 1.5%). Using a one-sided test, a 
standard deviation of 3.1 units,24 an α = 0.05, and an expected 10% attrition, a sample of 
225 participants in each arm would provide > 99% power to detect a within group reduction 
in FRS of 1.5 percentage points. This sample size would additionally provide 85% power to 
detect a 0.9 percentage point difference in FRS between the counselor and web arms (two-
sided test).
Analysis
We summarized baseline sample characteristics using descriptive statistics and compared 
groups using chi-square and t-tests. The primary outcome analysis was conducted using an 
intention-to-treat approach with a paired t-test (1-sided) for changes in FRS within each 
intervention arm. Additionally, for the primary outcome, we used multiple approaches for 
imputing missing data including last observations carried forward and multiple imputation 
methods.17
Secondary outcomes were examined using paired t-tests or McNemar’s tests for within 
group comparisons (2-sided tests). Additional analyses were conducted to compare the mean 
changes in FRS and other outcomes between arms using a simple t-test and a multivariable 
analysis of covariance model (ANCOVA) adjusting for the baseline value of the outcome, 
practice, and additional variables deemed relevant to behavior change a priori (age, race, 
educational achievement, and BMI) or that differed between intervention groups at baseline 
(p < 0.10). In addition, we conducted longitudinal analyses with FRS data from all 3 time 
points using generalized linear mixed models that included time, study groups, and time by 
study group interaction as fixed and participants as random effects along with site and the 
full set of covariates as fixed effects. To assess potential moderators of change in FRS, we 
used linear regression models that included the baseline FRS, the potential moderator of 
interest, and study arm by potential moderator interaction term.
For cost-effectiveness, we assessed the incremental cost effectiveness ratio (ICER) of each 
intervention from the payer, participant, and societal perspectives, as described in the 
Appendix. We calculate the ICER per 1 absolute percentage point reduction in CHD risk 
and per quality adjusted life year (QALY) gained at 12 months. We calculate QALY gained 
in one year by converting SF-12 scores into a health related quality of life weight using a 
well-defined algorithm.34 Because our analysis considers only a one year time horizon, this 
weight is equivalent to QALYs saved over this time period. We then report incremental 
cost-effectiveness per QALY gained and compare these ratios to common thresholds of 
cost-effectiveness. All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, 
NC) and Stata version 12 (StataCorp, College Station, TX) with p ≤ .05 considered 
significant.
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Enrollment and Baseline Characteristics of Participants
As depicted in Figure 1, of 2274 patients eligible to be screened for the study, 633 agreed to 
participate. Of these, 114 were ineligible because their FRS calculated using standardized 
measures was less than 10%, 111 took part in another intervention for those with known 
CVD as described elsewhere,17 23 were lost to follow-up or declined participation and 385 
participants took part in this study.
Table 1 reports baseline characteristics of study participants. The mean age was 62 years, 
24% were African American, 32% were employed full time, and 88% had health insurance. 
Overall, the sample was at high risk for CHD: 86% had current or previous high blood 
pressure, 85% had current or previous high blood cholesterol, 61% had diabetes, and the 
mean FRS was 16.9%. Also, two-thirds of participants reported they were comfortable or 
very comfortable using a computer.
Participants Choice of Risk Reducing Strategies, Intervention Participation, and Follow-up 
Rates
As noted in Figure 1, after viewing the decision aid, 366 (95%) participants elected to work 
on improving their diet, 256 (66%) chose to work on increasing their physical activity, 71 
(18%) decided to work on smoking cessation, and 142 (37%), chose to start or increase 
blood pressure or cholesterol medication or start aspirin.. Follow-up rates at 4 and 12 
months were 91% and 87%, respectively Those who did not return for follow-up at 4 
months were more likely to be white, younger, walk fewer minutes each week and at 12 
months, consume less fruit and vegetables and be less adherent to medications (p <0.05 for 
comparisons).
Study Outcomes
Change in study outcomes from baseline to follow-up, by treatment arm, are shown in Table 
2. For the FRS, there was a statistically significant and sustained reduction at both 4 
(primary outcome) and 12 month follow-up for participants in both study groups. For the 
counselor group, the change was −2.3% and −1.9% at 4 and 12 months, respectively. For the 
web group, it was −1.5% and −1.7%, respectively. When values of no change and multiple 
imputations methods were used to impute missing FRS scores, results did not change 
appreciably.
In both groups, all components of the FRS changed in the direction of decreased risk and the 
majority of changes were statistically significant and maintained from 4 to 12 month follow-
up. Likewise, most changes in diet and physical activity were in the direction of decreased 
risk and sustained over time. Moreover, there were substantial increases in appropriate use 
of and adherence with medication to reduce CHD risk. Other statistically significant 
outcomes of note include slight weight loss at 12 months, a reduction in A1c in the 
counselor group, and a sustained improvement in the physical component measure of quality 
of life in both groups.
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Self-reported results for tobacco cessation and aspirin use at follow-up were confirmed by 
biomarkers. Of 23 smokers who reported cessation, 18 (78%) were confirmed by urine 
cotinine testing and of 425 participants who reported aspirin use, 319 (75%) had serum 
thromboxane levels consistent with aspirin use.
The difference in study outcomes between treatment arms are shown in Table 3. At 4 month 
follow-up, the adjusted change (SE) in FRS was −2.4% (0.3) for counselor and −1.4% (0.3) 
for web, difference −1.0% (95% CI −1.8% to −0.1%, p = 0.03). At 12 month follow-up, the 
adjusted change (SE) in FRS −2.1% (0.4) for counselor and −1.5% (0.4) for web, difference 
−0.6% (95% CI, −1.7% to 0.5%, p = 0.30). When change in FRS was assessed by 
longitudinal analysis, there was no significant time by group interaction (p = 0.27) and 
within and between group comparisons were similar to analyses at each time point.
Sub-group analysis
Figure 2 shows the change in FRS at 4 and 12 month follow-up stratified on selected 
baseline variables. Assessing change in FRS by subgroups, without regard to treatment arm, 
the intervention was significantly more effective at 4 and 12 months among younger 
participants (P = .05 and <.001). In addition, at 4 month follow-up, the intervention was 
more effective among males (P = .04), those without diabetes (P = .02), and those choosing 
lifestyle and medication (P = .01). We noted little difference in the effectiveness of the 
counselor-delivered vs. web-based interventions when change in FRS was assessed by 
treatment arm and subgroups. At 4 month follow-up, there were a larger improvement in 
FRS among participants with diabetes in the counselor group (P for interaction = 0.03).
Adverse Outcomes
There were no reported adverse side effects related to dietary change or increased physical 
activity. Deaths due to CHD and newly diagnosed CHD are noted in Figure 1. There were 
no other deaths during follow-up. In addition, there was no material change in ALT or 
creatinine from baseline to follow-up.
Acceptability
Both counselor and web formats were well received. At 4 month follow-up, among 177 
counselor participants completing the acceptability survey, 137 (77%) strongly agreed and 
36 (20%) agreed that they would recommend this program to others. Similarly, among 173 
web participants, 128 (74%) strongly agreed and 42 24%) agreed with this statement. At 12 
month follow-up, among 170 counselor and 166 web participants completing the survey, 
166 (98%) counselor and 161 (97%) web participants would recommend or strongly 
recommend this program to others.
Cost Effectiveness
At 12 months, the costs per participant from the payer perspective were $207 (SE 3.4) and 
$110 (SE: 3.5) for the Counselor and Web interventions respectively (p<0.001). From the 
payer perspective, the incremental cost-effectiveness ratio for the less expensive Web 
intervention, compared to no intervention, was $73 per percentage point reduction in CHD 
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risk and $2,973 per QALY gained, which is considered very cost-effective based on 
common benchmarks35. Additional results are reported in the Appendix.
Sensitivity Analysis
A limited sensitivity analysis was conducted (Table 4) to assess change in 10-year risk for 
CHD as calculated with the Adult Treatment Panel (ATP) III risk calculator36 (which 
calculates MI and CHD death) and the Framingham risk calculator used for this study25 
without including a term for aspirin. Overall, results were similar, with significant 
reductions in estimated CHD risk in both groups at 4 and 12 month follow-up.
Discussion
In this comparative effectiveness trial, a combined lifestyle and medication intervention 
lowered predicted 10-year CHD risk within each treatment arm (pre-post change) at 4 and 
12 months. This risk reduction was achieved by improvements in lifestyle, medication use, 
or both and mediated through improvements in blood pressure, blood lipids, cigarette 
smoking, and aspirin use. The intervention was highly acceptable to participants, and the 
web format was cost effective based on established benchmarks.
These findings reinforce increasing evidence suggesting web-based interventions can have 
an important role in clinical practice.14,37,38 In this study, the web-based intervention was 
equally effective to the counselor-delivered intervention at 12 month follow-up. This 
suggests web interventions could be used to fill important gaps in counselor availability and, 
where counselors are available, allow counselors to focus their efforts on harder to change 
behaviors, such as refractory lifestyle behaviors.37 Web interventions might also be used to 
reach populations who have limited access to the clinic.
This study has several limitations. It was designed as a comparative effectiveness trial, 
without a no-intervention control group. Thus, observed changes could be due in part to 
regression to the mean (though baseline screening included two sequential assessments of 
FRS), secular trends, or other factors. Though non-intervention factors may account for 
some of the observed change, we believe much of the change was due to intervention effects 
as the components of the current intervention have previously been compared to no-
intervention control groups and have been shown to be effective.17 In a previous trial of a 
similar web-delivered medication intervention,24 the additional reduction in FRS between 
intervention and control groups at 3 month follow-up was 1.1 percentage points overall and 
1.4 percentage points among a pre-specified subgroup of participants with a 10-year 
predicted risk >10%. In a previous trial of a similar counselor-delivered dietary 
intervention,39 there was a substantial increase in fruit and vegetable intake, confirmed by 
blood carotenoids.
Additional limitations include many secondary outcomes that were self-reported behaviors, 
which may be exaggerated due to social desirability reporting bias, though we did measure 
biomarker change for fruit and vegetable intake, aspirin use, and smoking cessation. Also, 
we present many comparisons in our secondary analysis, and some p-values may be 
significant by chance. Our follow-up interval was 12 months, and the intervention effects 
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may attenuate over time. Further, our achieved sample size was somewhat less than our 
goal, decreasing power to detect between group differences. The generalizability of our 
findings may be limited to established, older patients who are at high risk for CHD. Finally, 
as lifestyle change may have beneficial effects on CHD risk independent of traditional risk 
factors,1,40 calculated change in FRS may underestimate intervention benefit.
In conclusion, the combined lifestyle and medication intervention tested in alternative 
formats yielded a substantial and sustained reduction in predicted 10-year CHD risk. Risk 
reduction was similar in both intervention formats at 12 month follow-up, though the web 
was less expensive to implement. Future research should assess the implementation and 
maintenance of high-quality evidence-based interventions in a broad selection of clinical 
settings. In addition, the lifestyle component of the interventions could be used, and should 
be studied, in non-clinical health promotion settings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This research was supported by the U.S. Centers for Disease Control and Prevention (CDC), American Recovery 
and Reinvestment Act of 2009, Cooperative Agreement Number 1U48DP002658 and also supported in part by 
National Institutes of Health grant P30DK056350 to the University of North Carolina at Chapel Hill Nutrition 
Obesity Research Center. The content is solely the responsibility of the authors, who give special thanks to: 1) 
participating practices in the North Carolina Family Medicine Research Network (Cabarrus Family Medical, 
Kannapolis, NC; Caswell Family Medical Center, Yanceyville, NC; Dayspring Family Medicine, Eden, NC; 
Durham Family Practice, Durham, NC; Moncure Community Health Center, Moncure, NC; 2) the health 
counselors who delivered interventions at these sites (Kim Grimm, Beth Jenks, Taimur Khan, Lauren Martin), 3) 
Russell Tracy, Ph.D and Elaine Cornell at the Laboratory for Clinical Biochemistry Research at the University of 
Vermont, and 4) the study participants, whole willing participation made this study possible.
Specific Role of Funding Agency
The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and 
interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the 
manuscript for publication.
References
1. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a 
Mediterranean diet. N Engl J Med. 2013; 368(14):1279–1290. [PubMed: 23432189] 
2. Mozaffarian D, Appel LJ, Van Horn L. Components of a cardioprotective diet: new insights. 
Circulation. 2011; 123(24):2870–2891. [PubMed: 21690503] 
3. Antithrombotic Trialists C, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary 
prevention of vascular disease: collaborative meta-analysis of individual participant data from 
randomised trials. Lancet. 2009; 373(9678):1849–1860. [PubMed: 19482214] 
4. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more 
intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 
randomised trials. Lancet. 2010; 376(9753):1670–1681. [PubMed: 21067804] 
5. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: 
improving the estimate of therapeutic benefit. J Hum Hypertens. 1996; 10(1):1–8. [PubMed: 
8642184] 
Keyserling et al. Page 10













6. Ammerman A, DeVellis R, Carey T, et al. Physician-based diet counseling for cholesterol 
reduction: current practices, determinants, and strategies for improvement. Prev Med. 1993; 22(1):
96–109. [PubMed: 8475015] 
7. Kushner RF. Barriers to providing nutrition counseling by physicians: a survey of primary care 
practitioners. Prev Med. 1995; 24(6):546–552. [PubMed: 8610076] 
8. Fineberg HV. The paradox of disease prevention: celebrated in principle, resisted in practice. 
JAMA. 2013; 310(1):85–90. [PubMed: 23821092] 
9. Centers for Disease Control and Prevention. [Accessed December 17, 2013] Ambulatory care use 
and physician visits. http://www.cdc.gov/Nchs/fastats/docvisit.htm
10. Ebrahim S, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary 
prevention of coronary heart disease. Cochrane Database Syst Rev. 2006; (4):CD001561. 
[PubMed: 17054138] 
11. Goldstein MG, Whitlock EP, DePue J. Multiple behavioral risk factor interventions in primary 
care. Summary of research evidence. Am J Prev Med. 2004; 27(2 Suppl):61–79. [PubMed: 
15275675] 
12. Slutsky JR, Clancy CM. Patient-centered comparative effectiveness research: essential for high-
quality care. Arch Intern Med. 2010; 170(5):403–404. [PubMed: 20212173] 
13. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research 
for decision making in clinical and health policy. JAMA. 2003; 290(12):1624–1632. [PubMed: 
14506122] 
14. Portnoy DB, Scott-Sheldon LA, Johnson BT, Carey MP. Computer-delivered interventions for 
health promotion and behavioral risk reduction: a meta-analysis of 75 randomized controlled trials, 
1988–2007. Prev Med. 2008; 47(1):3–16. [PubMed: 18403003] 
15. Ritterband LM, Tate DF. The science of internet interventions. Introduction. Ann Behav Med. 
2009; 38(1):1–3. [PubMed: 19816750] 
16. Noell J, Glasgow RE. Interactive technology applications for behavioral counseling: issues and 
opportunities for health care settings. Am J Prev Med. 1999; 17(4):269–274. [PubMed: 10606195] 
17. Sheridan SL, Draeger LB, Pignone MP, et al. Designing and implementing a comparative 
effectiveness study of two strategies for delivering high quality CHD prevention: Methods and 
participant characteristics for the Heart to Health study. Contemp Clin Trials. 2013; 36(2):394–
405. [PubMed: 23916919] 
18. Esposito K, Maiorino MI, Di Palo C, Giugliano D, Campanian Postprandial Hyperglycemia Study 
G. Adherence to a Mediterranean diet and glycaemic control in Type 2 diabetes mellitus. Diabet 
Med. 2009; 26(9):900–907. [PubMed: 19719711] 
19. Mozaffarian D. Effects of dietary fats versus carbohydrates on coronary heart disease: a review of 
the evidence. Curr Atheroscler Rep. 2005; 7(6):435–445. [PubMed: 16256001] 
20. Oh K, Hu FB, Manson JE, Stampfer MJ, Willett WC. Dietary fat intake and risk of coronary heart 
disease in women: 20 years of follow-up of the nurses' health study. Am J Epidemiol. 2005; 
161(7):672–679. [PubMed: 15781956] 
21. Pereira MA, O'Reilly E, Augustsson K, et al. Dietary fiber and risk of coronary heart disease: a 
pooled analysis of cohort studies. Arch Intern Med. 2004; 164(4):370–376. [PubMed: 14980987] 
22. Hamer M, Chida Y. Active commuting and cardiovascular risk: a meta-analytic review. Prev Med. 
2008; 46(1):9–13. [PubMed: 17475317] 
23. Zheng H, Orsini N, Amin J, Wolk A, Nguyen VT, Ehrlich F. Quantifying the dose-response of 
walking in reducing coronary heart disease risk: meta-analysis. Eur J Epidemiol. 2009; 24(4):181–
192. [PubMed: 19306107] 
24. Sheridan SL, Draeger LB, Pignone MP, et al. A randomized trial of an intervention to improve use 
and adherence to effective coronary heart disease prevention strategies. BMC Health Serv Res. 
2011; 11:331. [PubMed: 22141447] 
25. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart 
J. 1991; 121(1 Pt 2):293–298. [PubMed: 1985385] 
26. Jilcott SB, Keyserling TC, Samuel-Hodge CD, Johnston LF, Gross MD, Ammerman AS. 
Validation of a brief dietary assessment to guide counseling for cardiovascular disease risk 
Keyserling et al. Page 11













reduction in an underserved population. J Am Diet Assoc. 2007; 107(2):246–255. [PubMed: 
17258961] 
27. Schwartz LM, Woloshin S, Black WC, Welch HG. The role of numeracy in understanding the 
benefit of screening mammography. Ann Intern Med. 1997; 127(11):966–972. [PubMed: 
9412301] 
28. Davis TC, Long SW, Jackson RH, et al. Rapid estimate of adult literacy in medicine: a shortened 
screening instrument. Fam Med. 1993; 25(6):391–395. [PubMed: 8349060] 
29. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence 
measure in an outpatient setting. J Clin Hypertens. 2008; 10(5):348–354.
30. Block G, Gillespie C, Rosenbaum EH, Jenson C. A rapid food screener to assess fat and fruit and 
vegetable intake. Am J Prev Med. 2000; 18(4):284–288. [PubMed: 10788730] 
31. Kraschnewski JL, Gold AD, Gizlice Z, et al. Development and evaluation of a brief questionnaire 
to assess dietary fat quality in low-income overweight women in the southern United States. J Nutr 
Educ Behav. 2013; 45(4):355–361. [PubMed: 23340242] 
32. Giles-Corti B, Timperio A, Cutt H, et al. Development of a reliable measure of walking within and 
outside the local neighborhood: RESIDE's Neighborhood Physical Activity Questionnaire. Prev 
Med. 2006; 42(6):455–459. [PubMed: 16574208] 
33. Jones SA, Evenson KR, Johnston LF, et al. Psychometric properties of the modified RESIDE 
physical activity questionnaire among low-income overweight women. J Sci Med Sport. In Press. 
34. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med 
Care. 2004; 42(9):851–859. [PubMed: 15319610] 
35. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on 
generalized cost-effectiveness analysis. Health Econ. 2000; 9(3):235–251. [PubMed: 10790702] 
36. [Accessed March 16, 2014] Risk Assessment Tool for Estimating Your 10-year Risk of Having a 
Heart Attack. 2014. http://cvdrisk.nhlbi.nih.gov/calculator.asp
37. Glasgow RE, Bull SS, Piette JD, Steiner JF. Interactive behavior change technology. A partial 
solution to the competing demands of primary care. Am J Prev Med. 2004; 27(2 Suppl):80–87. 
[PubMed: 15275676] 
38. Linn AJ, Vervloet M, van Dijk L, Smit EG, Van Weert JC. Effects of eHealth interventions on 
medication adherence: a systematic review of the literature. J Med Internet Res. 2011; 13(4):e103. 
[PubMed: 22138112] 
39. Keyserling TC, Samuel Hodge CD, Jilcott SB, et al. Randomized trial of a clinic-based, 
community-supported, lifestyle intervention to improve physical activity and diet: The North 
Carolina enhanced WISEWOMAN project. Prev Med. 2008; 46(6):499–510. [PubMed: 18394692] 
40. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in 
secondary prevention of coronary heart disease. Lancet. 1994; 343(8911):1454–1459. [PubMed: 
7911176] 
Keyserling et al. Page 12













Figure 1. Study flow diagram
aNumber of smokers at baseline: 55 (counselor intervention) and 58 (web-based 
intervention)
bIncludes intent to start or increase blood pressure or cholesterol medication or start aspirin
Abbreviations: MI, myocardial infarction; CHD, coronary heart disease.
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Figure 2. Change in Framingham Risk Score, stratified on selected baseline variables, shown by 
treatment arm at 4 and 12 month follow-up
aAt 4 month follow-up, P-value ≤ .05 for comparison of FRS between sub-groups with web 
and counselor groups combined; bat 12 month follow-up, P-value ≤ .05 for same 
comparison.
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Age, mean (SE) 62 (0.4) 63 (0.5) 62 (0.6) 0.09
Female sex, No. (%) 186 (48) 102 (53) 84 (43) 0.06
Race, No. (%) 0.49
  African American 92 (24) 43 (22) 49 (25)
  White 292 (76) 150 (78) 142 (74)
Total household income, No. (%) 0.68
  < $20,000 87 (23) 39 (20) 48 (25)
  $20–39,999 112 (29) 61 (32) 51 (26)
  $40–69,999 70 (18) 33 (17) 37 (19)
  $70–99,999 37 (10) 19 (10) 18 (9)
  $100,000 or more 28 (7) 12 (6) 16 (8)
Currently employed full time, No. (%) 125 (32) 63 (33) 62 (32) 0.88
Health insurance, No. (%)a 0.24
  Commercial 248 (64) 125 (65) 123 (64)
  Medicare 62 (16) 35 (18) 27 (14)
  Medicaid 29 (7) 15 (8) 14 (7)
  No insurance 46 (12) 17 (9) 29 (15)
Education, No. (%) 0.68
  Less than high school 68 (18) 37 (19) 31 (16)
  High school 144 (37) 69 (36) 75 (39)
  College graduate or advanced degree 173 (45) 86 (45) 87 (45)
Less than 7–8th grade reading level, No. (%) 53 (14) 23 (12) 30 (15) 0.31
Risk factors for CHD, No. (%)
  High blood pressure 332 (86) 166 (86) 166 (86) 0.90
  High blood cholesterol 326 (85) 162 (84) 164 (85) 0.87
  Current smoker 113 (29) 55 (29) 58 (30) 0.76
  Diabetes 236 (61) 124 (65) 112 (58) 0.19
Medication use relevant to CHD risk reduction, No. (%)
  Taking blood pressure medicine 289 (75) 144 (75) 145 (75) 0.85
  Taking cholesterol medicine 236 (61) 119 (62) 117 (61) 0.78
  Taking aspirin (limited to males) 84 (42) 38 (42) 46 (42) 0.99
Factors affecting medication and lifestyle adherence, No. (%)
  Prescription drug plan 335 (87) 173 (90) 162 (84) 0.07
  Number of medications per day 0.27






















    None 10 (3) 6 (3) 4 (2)
    1–2 42 (11) 18 (9) 24 (12)
    3–5 144 (37) 69 (35) 75 (39)
    6–9 130 (34) 74 (38) 56 (29)
    10 or more 60 (16) 26 (13) 34 (18)
  Living with spouse or someone like spouse 263 (68) 124 (65) 139 (72) 0.12
  Comfort with computer 255 (66) 128 (67) 127 (66) 0.86
Other outcomes, mean (SE)
  Framingham Risk Scoreb 16.9 (0.3) 16.9 (0.4) 16.9 (0.4) 0.60
  Weight in kg 96 (1.1) 95 (1.6) 97 (1.5) 0.26
  BMI, kg/m2 33 (0.4) 33 (0.5) 34 (0.5) 0.71
  Systolic blood pressure 134 (0.9) 134 (1.2) 134 (1.3) 0.68
  Diastolic blood pressure 79 (0.6) 78 (0.7) 80 (0.9) 0.10
  Total cholesterol 194 (2.4) 197 (3.4) 190 (3.3) 0.14
  HDL-C 41 (0.5) 42 (0.8) 39 (0.7) 0.03
  LDL-C 122 (2.0) 125 (2.9) 119 (2.8) 0.26
  Hgb A1c 6.9 (0.1) 7.0 (0.1) 6.8 (0.1) 0.07
  hsCRP 4.7 (0.5) 4.9 (0.6) 4.6 (0.8) 0.29
  Fruit and vegetables servings/day 4.1 (0.1) 4.1 (0.1) 4.1 (0.1) 0.56
  Minutes of walking per week 77 (8.3) 74 (11.3) 79 (12.0) 0.63
  Steps per day (pedometer, n = 253) 4691 (168.4) 4604 (225.6) 4776 (250.0) 0.71
  Morisky medication adherence scale, No. (%) 0.75
    Low adherence 94 (27) 49 (29) 45 (26)
    Medium adherence 136 (39) 65 (39) 71 (40)
    High adherence 114 (33) 54 (32) 60 (34)
a
Categorized as commercial if participant had commercial and other insurance
b
Framingham risk scores calculated as percent chance of developing angina, myocardial infarction, or coronary heart disease death over a 10 year 
time frame
Abbreviations: CHD, coronary heart disease; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; Hgb A1c, hemoglobin A1c; hsCRP, high sensitivity C-reactive protein.
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